The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
Status:
Unknown status
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
This study will look at effects the combination of palbociclib and dose-dense neoadjuvant
chemotherapy may have on triple negative breast cancer tumours which have not yet been
treated.